- HUTCHMED (China) Limited (NASDAQ:HCM) announced the first presentation of results from the ongoing SAVANNAH Phase 2 trial at the upcoming World Conference on Lung Cancer.
- The study is evaluating savolitinib in combination with AstraZeneca Plc’s (NASDAQ:AZN) Tagrisso (osimertinib) in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors, following disease progression on Tagrisso.
- The abstract presents result from an analysis of 193 efficacy evaluable patients.
- Across all patients in this analysis, the objective response rate (ORR) was 32%, the median duration of response (DoR) was 8.3 months, and the median progression-free survival (PFS) was 5.3 months.
- These results are consistent with the previously presented results from the TATTON global exploratory study in over 220 EGFR mutation-positive NSCLC patients.
- Among the SAVANNAH patients who met the criteria for higher cut-off levels of MET aberration, ORR was 49%, median DoR was 9.3 months, and mPFS was 7.1 months.
- In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing and collaboration agreement to develop and commercialize savolitinib jointly.
- Price Action: HCM shares are up 0.60% at $13.48 during the market session on the last check Wednesday.
Purple Biotech Reports Results Of CM24 Dose Escalation In Advanced Pancreatic Cancer Patients
Purple's innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patients
Randomized Phase 2 study is enrolling as expected with initial Phase 2 data
